Q1 · MEDICINE
Article
Author: Kudchodkar, Sagar B ; Bah, Mamadou ; Durham, Amy C ; Park, Daniel H ; Broderick, Kate ; Esquivel, Rianne N ; Corti, Davide ; Choi, Hyeree ; Ramos, Stephanie ; Patel, Ami ; Mendoza, Janess ; Humeau, Laurent ; Shaheen, Shareef ; Allen, Jeffrey W ; Asija, Kanika ; Smith, Trevor R F ; Borole, Piyush ; Chen, Jing ; Stettler, Karin ; Muthumani, Kar ; Weiner, David B ; Beltramello, Martina ; Guibinga, Ghiabe ; Yan, Jian
Zika virus (ZIKV) infection is endemic to several world regions, and many others are at high risk for seasonal outbreaks. Synthetic DNA-encoded monoclonal antibody (DMAb) is an approach that enables in vivo delivery of highly potent mAbs to control infections. We engineered DMAb-ZK190, encoding the mAb ZK190 neutralizing antibody, which targets the ZIKV E protein DIII domain. In vivo-delivered DMAb-ZK190 achieved expression levels persisting >10 weeks in mice and >3 weeks in non-human primate (NHPs), which is protective against ZIKV infectious challenge. This study is the first demonstration of infectious disease control in NHPs following in vivo delivery of a nucleic acid-encoded antibody, supporting the importance of this new platform.